Positive Outlook for Epam Systems: Buy Rating with Raised Target Price
Analyst Mayank Tandon of Needham reiterated a Buy rating on Epam Systems (EPAM – Research Report), boosting the price target to $265.00.
Immunovant’s Promising Pipeline and Strategic Advancements Justify Buy Rating
LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Immunovant (IMVT – Research Report) today and set a price target of ...